Clinical Trial

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Strategic realignment
Summary
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-28.
Status change: Not Yet Recruiting → Withdrawn 2026-06-23
Trial Details
NCT Number NCT07100925
Lead Sponsor Ankyra Therapeutics, Inc
Conditions Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant, Solid Tumor, Solid Tumor Cancer
Start Date 2025-12-15
Primary Completion 2030-06 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-25